H1N1 flu variant may be resistant to certain treatments
NEW YORK — A new strain of swine flu has emerged that appears somewhat resistant to flu drugs, according to published reports.
Reuters reported that scientists in Australia and Singapore had found a variant of the H1N1 flu that showed some resistance to Roche’s Tamiflu (oseltamivir phosphate) and GlaxoSmithKline’s Relenza (zanamivir), though drug maker BioCryst currently is developing a drug called peramivir, to which the strain was not resistant.
Reuters reported that while the mutation had been found in some seasonal and H5N1 bird flu cases, it had not been found in the H1N1 strain.
While the World Health Organization said the pandemic ended in August 2010, the strain, which appeared in the United States and Mexico in 2009, has not disappeared.
Forest announces availability of Daliresp
NEW YORK — A drug for chronic obstructive pulmonary disease made by Forest Labs will be available by the middle of this month, Forest said Thursday.
Daliresp (roflumilast) recently received approval from the Food and Drug Administration as a treatment to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
Forest said Daliresp, a daily oral tablet, is the first and only approved drug in its class, known as selective phosphodiesterase-4 inhibitors.
JDRF, Selecta Biosciences collaborate on Type 1 diabetes vaccines development
NEW YORK and WATERTOWN, Mass. — The Juvenile Diabetes Research Foundation and Selecta Biosciences have established a research collaboration to develop vaccines for Type 1 diabetes, also known as juvenile diabetes.
Through the collaboration, JDRF will provide "milestone-based financial support and expertise" to Selecta, which ultimately would apply its vaccine technology to create a vaccine that would halt or prevent the autoimmune response that causes Type 1 diabetes.
The research collaboration between JDRF and Selecta is part of JDRF’s Industry Discovery and Development Partnership program, which launched in 2004.
"Through partnerships like this, JDRF is helping to speed the development of products from the lab to the marketplace, to make sure breakthroughs in science are able to reach the people they are meant to help," JDRF SVP strategic alliances Karin Hehenberger said. "Pooling the resources and strengths of both JDRF and Selecta allows us to work together to advance research that could help many people who have or are at risk for Type 1 diabetes, and we will be more effective in making these innovative products available to them."